{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:19:26Z","timestamp":1786709966378,"version":"build-2736575974"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.yebeh.2014.03.008","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T14:32:07Z","timestamp":1397485927000},"page":"105-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Use of antiepileptic drugs and lipid-lowering agents in the United States"],"prefix":"10.1016","volume":"34","author":[{"given":"Scott","family":"Mintzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yebeh.2014.03.008_bb0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e32833735e7","article-title":"Metabolic consequences of antiepileptic drugs","volume":"23","author":"Mintzer","year":"2010","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2014.03.008_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2014.03.008_bb0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11940-010-0080-y","article-title":"Antiepileptic drugs and markers of vascular risk","volume":"12","author":"Lopinto-Khoury","year":"2010","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2014.03.008_bb0020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.21615","article-title":"Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein","volume":"65","author":"Mintzer","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2014.03.008_bb0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2014.03.008_bb0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1254\/jphs.CRJ05003X","article-title":"The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins","volume":"98","author":"Hamed","year":"2005","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.yebeh.2014.03.008_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.wnl.0000341789.77291.8d","article-title":"Assessment of potential drug interactions in patients with epilepsy: impact of age and sex","volume":"72","author":"Gidal","year":"2009","journal-title":"Neurology"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2014.03.008_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eplepsyres.2010.07.021","article-title":"The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy","volume":"91","author":"Candrilli","year":"2010","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.yebeh.2014.03.008_bb0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-1211(99)00039-X","article-title":"Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group","volume":"37","author":"Brodie","year":"1999","journal-title":"Epilepsy Res"},{"issue":"11","key":"10.1016\/j.yebeh.2014.03.008_bb0040","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.WNL.0000167384.68207.3E","article-title":"New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine","volume":"64","author":"Rowan","year":"2005","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2014.03.008_bb0045","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yebeh.2005.06.001","article-title":"Treatment of epilepsy in adults: expert opinion, 2005","volume":"7","author":"Karceski","year":"2005","journal-title":"Epilepsy Behav"},{"issue":"12 Suppl. 4","key":"10.1016\/j.yebeh.2014.03.008_bb0050","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1212\/WNL.67.12_suppl_4.S56","article-title":"Optimizing therapy of seizures in women who use oral contraceptives","volume":"67","author":"Harden","year":"2006","journal-title":"Neurology"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505014000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T23:53:55Z","timestamp":1538697235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505014000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":12,"alternative-id":["S1525505014000894"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.03.008","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antiepileptic drugs and lipid-lowering agents in the United States","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2014.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}